Skip to Content

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

Ali Bazarbachi, MD, and PhD at the American University of Beirut in Lebanon, presents in this MEDtalk a report from the EBMT Acute Leukemia Working Party, showing improved post-transplant outcomes for AML patients with intermediate karyotype FLT3-ITD and wild type NPM1.

Ali Bazarbachi

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top